BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Sep 24, 2026; 17(9): 124416
Published online Sep 24, 2026. doi: 10.5306/wjco.124416
Table 2 Best overall response, n (%)

Anti-PD-1 plus cetuximab (n = 11)
Anti-PD-1 plus anlotinib (n = 10)
Best overall response
    Complete response1 (9.1)0 (0)
    Partial response2 (18.2)4 (40.0)
    Stable disease7 (63.6)6 (60.0)
    Progressive disease1 (9.1)0 (0)
ORR, %27.340.0
DCR, %90.9100


Write to the Help Desk